# Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma

Source: https://onco.cc/trials/nct06530823/  
OnCo record `nct06530823` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab and pemigatinib in gallbladder cancer and other biliary tract cancers, run by Eastern Hepatobiliary Surgery Hospital, not yet recruiting.

## Summary

Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma is a phase 2 interventional study registered as NCT06530823 by Eastern Hepatobiliary Surgery Hospital, with a registry enrolment figure of 38 participants, started 2024-08-01 and due to reach its primary completion in 2026-08-01. Interventions recorded: Pemigatinib and Durvalumab. Conditions listed: Biliary Tract Carcinoma, Cholangiocarcinoma. Gallbladder cancer is named in the registry entry: "3. Histologically confirmed advanced gallbladder cancer or cholangiocarcinoma patients who have received one prior line of therapy;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06530823
- Phase: 2
- Setting: Pemigatinib Combined With Durvalumab for the Safety and Efficacy in Second-Line Treatment of Biliary Tract Cancer: A Single-Arm, Multicenter Phase II Clinical Trial
- Sponsor: Eastern Hepatobiliary Surgery Hospital
- Enrolled: 38

## Sources

- ClinicalTrials.gov NCT06530823: https://clinicaltrials.gov/study/NCT06530823

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Pemigatinib](https://onco.cc/drugs/pemigatinib/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06530823.json